To print: Select File and then Print from your browser's menu

Title: Omapatrilat Benefits Patients with Chronic Heart Failure Over Lisinopril

URL: http://www.cardiosource.com/journal/journal/article?
acronym=AJC&format=abstract&uid=PIIS0002914902025213

The American Journal of Cardiology 2002, Vol 90, Issue 5;496-500. "Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure"
09/27/2002 02:27:56 PM
By David Ball

C-terminal atrial natriuretic peptide (C-ANP) is potentiated more by omapatrilat than lisinopril, even at trough levels, say Canadian, United States and Norwegian researchers. They identified potentially important effects of omapatrilat on endothelin-1 and anti-inflammatory cytokines in patients with chronic heart failure. Differences in clinical outcome might be explained by these findings, suggest investigators at the University of Toronto and University Health Network, St. Michael's Hospital, Ontario; Universite de Montreal, Quebec, Canada; Bristol-Myers Squibb, New Jersey; Brigham and Women's Hospital, Boston, United States; and University of Oslo, Norway. They point out that the effects of angiotensin-converting enzyme (ACE) inhibitors modulate the neurohumoral milieu. In patients with congestive heart failure, natriuretic peptides, bradykinin, and possibly endothelin-1 may be increased by asopeptidase inhibitors (VPI) which are ACE and neutral endopeptidase inhibitors. One hundred and seven subjects with ischemic or dilated cardiomyopathy, New York Heart Association functional class II to III, with left ventricular ejection fraction of less than 40 percent were included in this study. All were receiving treatment with ACE inhibitors and were randomly assigned to two groups for either the VPI omapatrilat 40 mg/day or the ACE inhibitor lisinopril 20 mg/day. Assessments were made of trough levels of neurohormones (24 hours after dosing) at baseline and at 12 and 24 weeks of follow-up. C-ANP levels were found to decrease with lisinopril (p = 0.035), though not with omapatrilat. No change was seen, however, in N-terminal ANP levels. Both groups showed a tendency for a similar decrease in brain natriuretic peptide (BNP) levels. Both had increased endothelin-1 levels, which was statistically significant with omapatrilat (p = 0.008). While a decrease was seen in levels of the proinflammatory cytokine interleukin-6, there was an increase in both groups of the anti-inflammatory cytokine interleukin-10. The only statistical significance for interleukin-10, however, was shown with omapatrilat therapy. Catecholamines or angiotensin II were unchanged by either agent.

http://www.cardiosource.com/journal/journal/article?
acronym=AJC&format=abstract&uid=PIIS0002914902025213

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.